[company_age]7.0[/company_age][employees]2-10 employees[/employees][funding]Seed[/funding][description]FluoretiQ Limited is a Bristol-based medical device company dedicated to revolutionizing bacterial identification and antibiotic stewardship. Their mission is to empower clinicians with rapid, accurate, and point-of-care diagnostic tools that enable informed treatment decisions, ultimately saving time, lives, and antibiotics. FluoretiQ's unique approach tackles the global challenge of antimicrobial resistance (AMR) by promoting evidence-based antibiotic prescriptions and minimizing unnecessary antibiotic use. Their two flagship technologies, NANOPLEX® and SCFI™, address crucial questions in infection management: identifying the cause of infection and determining the most effective antibiotic treatment. NANOPLEX® rapidly identifies and quantifies the cause of infection within 5 minutes, while SCFI™ determines the most effective antibiotic in just 30 minutes. This real-time information empowers clinicians to initiate appropriate treatment promptly, improving patient outcomes and curbing the rise of AMR. FluoretiQ's commitment to innovation and impact is evident in their collaborations with leading healthcare institutions and their dedication to developing a comprehensive suite of diagnostic tools. Their team of experts, led by CEO Neciah Dorh and CTO Josephine Dorh, brings together diverse expertise in engineering, medicine, and business, driving the company's mission forward.[/description][ps]NANOPLEX® (bacterial identification) and SCFI™ (antibiotic susceptibility testing)[/ps]